Latest Headlines

31. Simtra BioPharma Solutions And MilliporeSigma Announce Strategic Alliance For Antibody Drug Conjugates Drug Substance And Drug Product Manufacturing Services 6/12/2025
32. CDMO Bora Biologics Announces Plans To Expand San Diego Manufacturing Facility 5/22/2025

    Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego. This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics' position as a premier biologics CDMO.

33. Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy 5/15/2025

    Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC).

34. VintaBio Presents Data Demonstrating High-Efficiency AAV Vector Production Using Proprietary VintaProcess™ At 2025 ASGCT Annual Meeting 5/15/2025

    VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary VintaProcess™ at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.  

35. NanoTemper Announces Prometheus Panta C: Powering Biopharma Breakthroughs From Preclinical To Commercial Manufacturing 5/12/2025

    NanoTemper Technologies today introduces Prometheus Panta C, a system built to power biopharma breakthroughs by delivering high-quality protein stability and aggregation data.

36. Andelyn Biosciences Applies The AAV Curator® Platform To Deliver Novel Gene Therapy For An Ultra-Rare NEDAMSS Disease Patient 14-Months After Diagnosis 5/12/2025

    Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has successfully manufactured a novel viral vector gene therapy with its AAV Curator® Platform to treat a baby with the ultra-rare disease Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS).

37. VintaBio Unveils New Data Showcasing Scalable AAV Perfusion Manufacturing Platform With High Full Capsid Yield At 2025 ASGCT Annual Meeting 5/8/2025

    VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present transformative data on its proprietary VintaProcess™, an advanced intensified adherent viral vector manufacturing platform.

38. Minaris Advanced Therapies Launches As The Leading Global Partner Dedicated To Cell Therapy Development, Manufacturing, And Testing 5/7/2025

    Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi Advanced Therapies have been combined to form Minaris Advanced Therapies, a global cell therapy CDMO and testing partner.

39. Merck Breaks Ground On New Biologics And ADC Manufacturing Facility In Delaware 4/29/2025

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, Delaware.

40. RoosterBio Announces Collaboration With Thermo Fisher Scientific To Advance Cell And Exosome Therapy Manufacturing 4/29/2025

    RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science.